论文部分内容阅读
目的:探讨肺表面活性物质(PS)治疗新生儿重症胎粪吸入综合征(MAS)的临床疗效。方法:将新生儿MAS患儿52例随机分为治疗组和对照组各26例。两组均给予上呼吸机及常规治疗,治疗组在气道充分灌洗后应用肺表面活性物质(固尔苏)100～150 mg/kg气管内给药。观察两组患儿的氧合功能、病程及预后,并进行统计学分析。结果:治疗组患儿的氧合指数低于对照组(P<0.05),动脉/肺泡氧分压比值高于对照组(P<0.05),治疗组上机时间、住院时间、并发气胸和呼吸机相关性肺炎(VAP)均少于对照组(P<0.05)。结论:肺表面活性物质能有效改善MAS患儿的肺氧合功能,缩短机械通气时间、住院时间及病程,减少气胸及VAP的发生。
Objective: To investigate the clinical efficacy of pulmonary surfactant (PS) in the treatment of neonatal severe meconium aspiration syndrome (MAS). Methods: Fifty-two neonates with MAS were randomly divided into treatment group and control group, with 26 cases each. Both groups were given the ventilator and routine treatment. The treatment group was given tracheal administration of 100-150 mg / kg of pulmonary surfactant (Culbesil) after adequate lavage of the airway. The oxygenation function, course and prognosis of the two groups were observed and statistically analyzed. Results: The oxygenation index of the treatment group was lower than that of the control group (P <0.05), and the ratio of arterial to alveolar oxygen partial pressure was higher than that of the control group (P <0.05). The treatment time, hospital stay, pneumothorax and respiration Machine-related pneumonia (VAP) were less than the control group (P <0.05). CONCLUSIONS: Pulmonary surfactant can effectively improve pulmonary oxygenation in children with MAS, shorten the duration of mechanical ventilation, duration of hospitalization and duration of disease, and reduce the occurrence of pneumothorax and VAP.